Bilosomes and Biloparticles for the Delivery of Lipophilic Drugs: A Preliminary Study

Overview

Journal Antioxidants (Basel)

Date 2023 Dec 23

PMID 38136145

Authors

Maddalena Sguizzato

Francesca Ferrara

Nada Baraldo

Agnese Bondi

Annunziata Guarino

Markus Drechsler

Giuseppe Valacchi

Rita Cortesi

Affiliations

Soon will be listed here.

Abstract

In this study, bile acid-based vesicles and nanoparticles (i.e., bilosomes and biloparticles) are studied to improve the water solubility of lipophilic drugs. Ursodeoxycholic acid, sodium cholate, sodium taurocholate and budesonide were used as bile acids and model drugs, respectively. Bilosomes and biloparticles were prepared following standard protocols with minor changes, after a preformulation study. The obtained systems showed good encapsulation efficiency and dimensional stability. Particularly, for biloparticles, the increase in encapsulation efficiency followed the order ursodeoxycholic acid < sodium cholate < sodium taurocholate. The in vitro release of budesonide from both bilosytems was performed by means of dialysis using either a nylon membrane or a portion of Wistar rat small intestine and two receiving solutions (i.e., simulated gastric and intestinal fluids). Both in gastric and intestinal fluid, budesonide was released from bilosystems more slowly than the reference solution, while biloparticles showed a significant improvement in the passage of budesonide into aqueous solution. Immunofluorescence experiments indicated that ursodeoxycholic acid bilosomes containing budesonide are effective in reducing the inflammatory response induced by glucose oxidase stimuli and counteract ox-inflammatory damage within intestinal cells.

References

Cortesi R, Esposito E, Drechsler M, Pavoni G, Cacciatore I, Sguizzato M . L-dopa co-drugs in nanostructured lipid carriers: A comparative study. Mater Sci Eng C Mater Biol Appl. 2016; 72:168-176. DOI: 10.1016/j.msec.2016.11.060. View

Shukla A, Mishra V, Kesharwani P . Bilosomes in the context of oral immunization: development, challenges and opportunities. Drug Discov Today. 2016; 21(6):888-99. DOI: 10.1016/j.drudis.2016.03.013. View

Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A . Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018; 10(2). PMC: 6027495. DOI: 10.3390/pharmaceutics10020057. View

Charman W . Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharm Sci. 2000; 89(8):967-78. DOI: 10.1002/1520-6017(200008)89:8<967::aid-jps1>3.0.co;2-r. View

Ferrara F, Pecorelli A, Valacchi G . Redox Regulation of Nucleotide-Binding and Oligomerization Domain-Like Receptors Inflammasome. Antioxid Redox Signal. 2023; 39(10-12):744-770. DOI: 10.1089/ars.2022.0180. View

Gregoriadis G . Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol. 1995; 13(12):527-37. DOI: 10.1016/S0167-7799(00)89017-4. View

Mohsen A, Hasanein Asfour M, Salama A . Improved hepatoprotective activity of silymarin via encapsulation in the novel vesicular nanosystem bilosomes. Drug Dev Ind Pharm. 2017; 43(12):2043-2054. DOI: 10.1080/03639045.2017.1361968. View

Zarenezhad E, Marzi M, Abdulabbas H, Jasim S, Kouhpayeh S, Barbaresi S . Bilosomes as Nanocarriers for the Drug and Vaccine Delivery against Gastrointestinal Infections: Opportunities and Challenges. J Funct Biomater. 2023; 14(9). PMC: 10531812. DOI: 10.3390/jfb14090453. View

Sguizzato M, Ferrara F, Drechsler M, Baldisserotto A, Montesi L, Manfredini S . Lipid-Based Nanosystems for the Topical Application of Ferulic Acid: A Comparative Study. Pharmaceutics. 2023; 15(7). PMC: 10385185. DOI: 10.3390/pharmaceutics15071940. View

10.

Liu C, Liu Y, Wang C, Guo Y, Cheng Y, Qian H . Lycopene-Loaded Bilosomes Ameliorate High-Fat Diet-Induced Chronic Nephritis in Mice through the TLR4/MyD88 Inflammatory Pathway. Foods. 2022; 11(19). PMC: 9564075. DOI: 10.3390/foods11193042. View

11.

Ahmad J, Singhal M, Amin S, Rizwanullah M, Akhter S, Kamal M . Bile Salt Stabilized Vesicles (Bilosomes): A Novel Nano-Pharmaceutical Design for Oral Delivery of Proteins and Peptides. Curr Pharm Des. 2017; 23(11):1575-1588. DOI: 10.2174/1381612823666170124111142. View

12.

Binsuwaidan R, Sultan A, Negm W, Attallah N, Alqahtani M, Hussein I . Bilosomes as Nanoplatform for Oral Delivery and Modulated In Vivo Antimicrobial Activity of Lycopene. Pharmaceuticals (Basel). 2022; 15(9). PMC: 9505130. DOI: 10.3390/ph15091043. View

13.

Aburahma M . Bile salts-containing vesicles: promising pharmaceutical carriers for oral delivery of poorly water-soluble drugs and peptide/protein-based therapeutics or vaccines. Drug Deliv. 2014; 23(6):1847-67. DOI: 10.3109/10717544.2014.976892. View

14.

Esposito E, Sguizzato M, Drechsler M, Mariani P, Carducci F, Nastruzzi C . Progesterone lipid nanoparticles: Scaling up and in vivo human study. Eur J Pharm Biopharm. 2017; 119:437-446. DOI: 10.1016/j.ejpb.2017.07.015. View

15.

Aditya N, Gonzalez Espinosa Y, Norton I . Encapsulation systems for the delivery of hydrophilic nutraceuticals: Food application. Biotechnol Adv. 2017; 35(4):450-457. DOI: 10.1016/j.biotechadv.2017.03.012. View

16.

Valacchi G, Virgili F, Cervellati C, Pecorelli A . OxInflammation: From Subclinical Condition to Pathological Biomarker. Front Physiol. 2018; 9:858. PMC: 6046448. DOI: 10.3389/fphys.2018.00858. View

17.

Liu L, Yao W, Rao Y, Lu X, Gao J . pH-Responsive carriers for oral drug delivery: challenges and opportunities of current platforms. Drug Deliv. 2017; 24(1):569-581. PMC: 8241197. DOI: 10.1080/10717544.2017.1279238. View

18.

Lv Q, Xu D, Ma J, Wang Y, Yang X, Zhao P . Uric acid drives intestinal barrier dysfunction through TSPO-mediated NLRP3 inflammasome activation. Inflamm Res. 2020; 70(1):127-137. DOI: 10.1007/s00011-020-01409-y. View

19.

Vrettos N, Roberts C, Zhu Z . Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications. Pharmaceutics. 2021; 13(10). PMC: 8539558. DOI: 10.3390/pharmaceutics13101591. View

20.

Siepmann J, Peppas N . Higuchi equation: derivation, applications, use and misuse. Int J Pharm. 2011; 418(1):6-12. DOI: 10.1016/j.ijpharm.2011.03.051. View